Billing and drug-code restrictions

Drug codes not covered when delivered by iontophoresis — Certain drug and HCPCS/J-codes are noted as not covered when administered via iontophoresis. Examples include J3285 (treprostinil injection) and J7686 (treprostinil inhalation solution) when billed based on iontophoretic administration; other investigational formulations (e.g., gold nanoparticles, nanoethosomal piroxicam, acetic acid, ascorbic acid) have no specific code and are considered not covered for the experimental indications listed in the policy.

• Affected codes: J3285, J7686
• Investigational/no specific code examples: gold nanoparticles with iontophoresis, nanoethosomal piroxicam, acetic acid iontophoresis, ascorbic acid iontophoresis

Procedural/coding denials

No explicit procedural or coding denial triggers specified — The policy does not define additional procedural or coding denial rules beyond the coverage and non-coverage code lists; providers should follow the CPT/HCPCS/ICD-10 listings in the policy and submit documentation that meets the medical necessity criteria.

• Follow covered CPT codes (e.g., 97033, 89230) when selection criteria are met
• Non-covered/experimental code examples are listed in the policy chunks

Prior authorization / denial criteria

No authorization or denial criteria provided in this excerpt — The policy sections included do not state explicit prior authorization requirements or operational denial criteria; when prior authorization is required by the payer or plan, providers must follow plan-specific authorization processes.

• Check plan-level prior authorization rules for CPT 97033 and CPT 89230 where applicable
• Policy history and additional resources do not list authorization workflows

Clinical trial measurement notes

Clinical trial descriptions include objective measurements and patient questionnaires — The evidence summary and trial reports referenced in the policy describe objective outcome measures (e.g., sweat chloride concentration for cystic fibrosis diagnosis, keratometry and UCVA for keratoconus trials, pain scores and functional assessments in musculoskeletal studies) and use validated patient questionnaires in some trials.

• Sweat test: pilocarpine iontophoresis with measured chloride concentration (>60 mEq/L confirms CF)
• Keratoconus trials: maximum keratometry and UCVA at 12 months
• Musculoskeletal trials: patient-reported pain measures and validated questionnaires

Conservative-first approach for hyperhidrosis

Conservative-first approach (informational) — Topical antiperspirants (e.g., aluminum chloride) are typically tried before iontophoresis for primary focal hyperhidrosis; iontophoresis is considered when topical therapies and oral pharmacotherapy are ineffective or not tolerated.

• Step sequence for hyperhidrosis: topical antiperspirants → oral pharmacotherapy (if used) → iontophoresis for intractable, disabling primary focal hyperhidrosis

Iontophoresis for plantar fasciitis / heel pain (informational)

For plantar fasciitis/heel pain, iontophoresis protocols referenced in the literature are small-trial and not established as standard requirement — examples include a 0.4% dexamethasone protocol (6 sessions) and studies using acetic acid; these trials showed short-term or inconsistent benefit and are not listed as recommended standard care in the policy.

• Small randomized trial: iontophoresis with 0.4% dexamethasone, 6 sessions over 2 weeks — moderate initial relief not maintained at 4 weeks
• Other small studies: acetic acid iontophoresis results inconsistent and not included in summary recommendations

Step therapy and trial requirements

No step therapy requirements described in these policy excerpts — Apart from the conservative-first note for hyperhidrosis (topical antiperspirants before iontophoresis), the policy chunks do not specify formal step-therapy protocols or mandatory trials beyond the stated medical necessity criteria.

• Documented trials required where specified in medical necessity criteria (e.g., failure/intolerance of oral pharmacotherapy and topical aluminum chloride for hyperhidrosis)
• No additional step-therapy rules provided in the policy excerpts

Policy history and administrative dates

Policy includes review history and effective/next review dates — The policy history and administrative information are present in the source: effective date (04/22/1998), last review (04/26/2023), and next review (02/22/2024).

• Effective date: 04/22/1998
• Last review: 04/26/2023
• Next review: 02/22/2024